In a new research, a group of researchers have developed a nanowire device that can detect microscopic levels of cancer markers in the urine, an advance that could help non-invasively diagnose the deadly disease.
Cells communicate with each other through a number of different mechanisms.
A less familiar mode of cellular transport is the extracellular vesicle (EV), which can be thought of as small "chunks" of a cell that are able to pinch off and circulate throughout the body to deliver messenger cargo to other cells.
These messengers have become increasingly recognised as crucial mediators of cell-to-cell communication.
The scientists have developed a novel medical device that can efficiently capture these EVs, and potentially use them to screen for cancer.
Talking about the research, study's lead author Takao Yasui explained, "EVs are potentially useful as clinical markers. The composition of the molecules contained in an EV may provide a diagnostic signature for certain diseases. The ongoing challenge for physicians in any field is to find a non-invasive diagnostic tool that allows them to monitor their patients on a regular basis -- for example, a simple urine test."
Yasui further added, "The content of EVs in urine is extremely low, at less than 0.01 percent of the total fluid volume. This is a major barrier to their diagnostic utility. Our solution was to embed zinc oxide nanowires into a specialized polymer to create a material that we believed would be highly efficient at capturing these vesicles. Our findings suggest that the device is indeed quite efficient. We obtained a collection rate of over 99 percent, surpassing ultracentrifugation as well as other methods that are currently being used in the field."
To test the practicality of their device, researchers compared the microRNAs of EVs isolated from healthy patients with those isolated from patients who were already diagnosed with bladder, prostate, and other forms of cancer.
The technique required only one millilitre of urine and found a substantially greater number and different types of microRNAs compared with the standard ultracentrifugation approach.
The study was published in journal Science Advances.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
